Dotarizine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Dotarizine
Dotarizine.png
Systematic (IUPAC) name
1-[diphenylmethyl]-4-[3-(2-phenyl-1,3-dioxolan-2-yl)propyl]piperazine
Clinical data
Legal status
?
Identifiers
CAS number 84625-59-2 YesY
ATC code None
PubChem CID 55285
UNII IO7663S6D3 N
Synonyms Dotarizine
Chemical data
Formula C29H34N2O2 
Mol. mass 442.592 g/mol
 N (what is this?)  (verify)

Dotarizine is a drug used in the treatment of migraine,[1] which acts as a calcium channel blocker,[2] and also as an antagonist at the 5HT2A receptor, and to a lesser extent at the 5HT1A and 5HT2C receptors.[3][4] The anti-migraine action is thought to be due to its action as a vasodilator,[5][6] but it also has some anxiolytic effects[7] and blocks amnesia produced by electroconvulsive shock in animals.[8]

References[edit]

  1. ^ Ruiz-Nuño, A; Villarroya, M; Cano-Abad, M; Rosado, A; Balfagón, G; López, MG; García, AG (2001). "Mechanisms of blockade by the novel migraine prophylactic agent, dotarizine, of various brain and peripheral vessel contractility". European Journal of Pharmacology 411 (3): 289–99. doi:10.1016/S0014-2999(00)00897-9. PMID 11164387. 
  2. ^ Ruiz-Nuño, A; Mayorgas, I; Hernández-Guijo, JM; Olivares, R; García, AG; Gandía, L (2003). "Antimigraine dotarizine blocks P/Q Ca2+ channels and exocytosis in a voltage-dependent manner in chromaffin cells". European Journal of Pharmacology 481 (1): 41–50. doi:10.1016/j.ejphar.2003.09.013. PMID 14637173. 
  3. ^ Farré, M; Roset, PN; Llorente, M; Márquez, M; Albet, C; Pérez, JA; Herrero, E; Ortíz, JA (1997). "Clinical pharmacokinetics and tolerability of dotarizine in healthy subjects after single and multiple oral administration". Methods and findings in experimental and clinical pharmacology 19 (5): 343–50. PMID 9379783. 
  4. ^ Montiel, C; Herrero, CJ; García-Palomero, E; Renart, J; García, AG; Lomax, RB (1997). "Serotonergic effects of dotarizine in coronary artery and in oocytes expressing 5-HT2 receptors". European Journal of Pharmacology 332 (2): 183–93. doi:10.1016/S0014-2999(97)01073-X. PMID 9286620. 
  5. ^ Kuridze, N; Gajkowska, B; Czernicki, Z; Jurkiewicz, J; Cervos-Navarro, J (1998). "The effect of Dotarizine--(Ca2+ channel blocker)--on vascular reactivity and ultrastructure of cerebral capillaries in animals subjected to anoxia". Folia neuropathologica / Association of Polish Neuropathologists and Medical Research Centre, Polish Academy of Sciences 36 (2): 101–8. PMID 9757621. 
  6. ^ Kuridze, N; Czernicki, Z; Jarus-Dziedzic, K; Jurkiewicz, J; Cervos-Navarro, J (2000). "Regional differences of cerebrovascular reactivity effected by calcium channel blocker - dotarizine". Journal of the neurological sciences 175 (1): 13–6. doi:10.1016/S0022-510X(00)00275-6. PMID 10785251. 
  7. ^ Petkov, VD; Belcheva, S; Konstantinova, E (1995). "Anxiolytic effects of dotarizine, a possible antimigraine drug". Methods and findings in experimental and clinical pharmacology 17 (10): 659–68. PMID 9053586. 
  8. ^ Lazarova, M; Petkova, B; Petkov, VD (1995). "Effect of dotarizine on electroconvulsive shock or pentylenetetrazol-induced amnesia and on seizure reactivity in rats". Methods and findings in experimental and clinical pharmacology 17 (1): 53–8. PMID 7623521.